BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phas...

March 05, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

WuXi Biologics Passes Japan’s PMDA GMP Inspection for Wuxi Drug Substance Facilities

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has...

February 28, 2025 | News

CARsgen Doses First SLE Patient with KJ-C2219, a Dual-Target Allogeneic CAR-T Therapy

CARsgen Therapeutics Holdings Limited a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tu...

February 28, 2025 | News

Ping An Health Launches AI-Powered "Ping An Xin Yi" Digital Doctor for 24/7 Smart Healthcare

Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently annou...

February 27, 2025 | News

Fosun Pharma Secures NMPA Approval for Tenapanor, Bringing New Hope to Dialysis Patients in China

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharm...

February 27, 2025 | News

ZEISS’s Next-Generation VISUMAX® 800 with SMILE® Pro Secures NMPA Approval for Laser Vision Correction in China

ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) in China has approved the VISUMAX® 800 with ...

February 27, 2025 | News

Biocair Opens a New Site in Chengdu, China

The new site marks Biocair’s eighth location in the Asia-Pacific region. Biocair reinforces the importance of de...

February 26, 2025 | News

WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development

WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...

February 26, 2025 | News

MicuRx’s MRX-4 and Contezolid Show Favorable Safety and Efficacy in Phase III Trial for Diabetic Foot Infections

Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued pro...

February 26, 2025 | News

Kangpu Biopharma Secures China IND Approval for KPG-818 in Relapsed/Refractory Multiple Myeloma

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National...

February 26, 2025 | News

Stay Connected